Back to results
US 11,730,762 B2Granted
Methods for stimulating proliferation or differentiation of an immune cell with a multi-chain chimeric polypeptide
AssigneeHCW Biologics, Inc.
InventorHing Wong
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the field of biotechnology, and more specifically, to single-chain and multi-chain chimeric polypeptides having a linker domain positioned between two target-binding domains that are useful for a variety of applications including, without limitation, stimulating an immune cell, inducing or increasing proliferation of an immune cell, inducing differentiation of an immune cell, or treating a subject in need thereof (e.g., a subject having cancer or an aging-related disease or condition).
Claims28
A method of promoting the activation and proliferation of a natural killer cell or a T cell, the method comprising:
- contacting a natural killer cell or a T cell in a liquid culture medium comprising:
- (1) an effective amount of a multi-chain chimeric polypeptide comprising:
- (a) a first chimeric polypeptide comprising:
- (i) a first target-binding domain;
- (ii) a soluble tissue factor domain comprising a sequence that is at least 90% identical to SEQ ID NO:
- 1;
- and
- (iii) a first domain of a pair of affinity domains comprising a sequence that is at least 90% identical to SEQ ID NO:
- 39;
- (b) a second chimeric polypeptide comprising:
- (i) a second domain of a pair of affinity domains comprising a sequence that is at least 90% identical to SEQ ID NO:
- 10;
- and
- (ii) a second target-binding domain,
- wherein the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the pair of affinity domains, and
- wherein:
- (A) the first target-binding domain comprises a sequence that is at least 90% identical to SEQ ID NO:
- 135 and the second target-binding domain comprises a sequence that is at least 90% identical to SEQ ID NO:
- 124;
- (B) the first target-binding domain comprises a sequence that is at least 90% identical to SEQ ID NO:
- 124 and the second target-binding domain comprises a sequence that is at least 90% identical to SEQ ID NO:
- 135;
- or
- (C) the first target-binding domain comprises a sequence that is at least 90% identical to SEQ ID NO:
- 124 and the second target-binding domain comprises a sequence that is at least 90% identical to SEQ ID NO:
- 60;
- and
- (2) an effective amount of an IgG1 antibody construct comprising at least one antigen-binding domain that binds specifically to the soluble tissue factor domain,
- under conditions that allow for the activation and proliferation of the natural killer cell or the T cell.
26 more elements
Dependencies are inferred from the claim text.